Terns Pharmaceuticals Inc expected to post a loss of 31 cents a share - Earnings Preview

Terns Pharmaceuticals

03/11/2023 12:01

* Terns Pharmaceuticals Inc  TERN.OQ   TERN.O  is expected
to show
no change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Terns
Pharmaceuticals Inc
is for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Terns
Pharmaceuticals Inc is $17​, above​ its last closing price
of $4.83. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.34       -0.34      -0.25     Beat    26.2
 Mar. 31 2023  -0.27       -0.27      -0.31     Missed  -15.8
 Dec. 31 2022  -0.39       -0.43      -0.29     Beat    32.6​
 Sep. 30 2022  -0.47       -0.52      -0.44     Beat    15.4
 ​​Jun.        -0.56       -0.59      -0.55     Beat    7.3
 30 2022                                                
 Mar. 31 2022  -0.66       -0.64      -0.55     Beat    14.5​
 Dec. 31 2021  -0.62       -0.63      -0.56     Beat    10.6
 Sep. 30 2021  -0.66       -0.60      -0.47     Beat    22.1
 This summary was machine generated November 3 at 12:01 GMT.  All
figures in US dollars  unless otherwise stated